Antibody Response to SARS-CoV-2 Vaccination in Patients following Allogeneic Hematopoietic Cell Transplantation
Open Access
- 31 January 2022
- journal article
- research article
- Published by Elsevier in Transplantation and Cellular Therapy
- Vol. 28 (4) , 214.e1-214.e11
Abstract
No abstract availableKeywords
This publication has 31 references indexed in Scilit:
- Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort studyThe Lancet Haematology, 2020
- Measuring SARS-CoV-2 neutralizing antibody activity using pseudotyped and chimeric virusesJournal of Experimental Medicine, 2020
- COVID-19 outcomes in patients with hematologic diseaseBone Marrow Transplantation, 2020
- How I vaccinate blood and marrow transplant recipientsBlood, 2016
- Co-transplantation of pure blood stem cells with antigen-specific but not bulk T cells augments functional immunityProceedings of the National Academy of Sciences, 2012
- Allogeneic T cells impair engraftment and hematopoiesis after stem cell transplantationProceedings of the National Academy of Sciences, 2010
- The Burden of Bacterial and Viral Infections in Hematopoietic Stem Cell TransplantTransplantation and Cellular Therapy, 2009
- Reconstitution of the immune system after hematopoietic stem cell transplantation in humansSeminars in Immunopathology, 2008
- Why Aging T Cells Fail: Implications for VaccinationImmunity, 2006
- Immune reconstitution after allogeneic marrow transplantation compared with blood stem cell transplantationBlood, 2001